134 related articles for article (PubMed ID: 24397109)
1. Granulocyte-colony stimulating factor for mobilizing bone marrow stem cells in the sub acute stroke. How safe is the use of granulocyte-colony stimulating factor in sub-acute stroke? Is this stem cell trial of recovery enhancement beneficial?
Nomani F; Kamal AK
J Pak Med Assoc; 2013 Dec; 63(12):1558-9. PubMed ID: 24397109
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte-colony stimulating factor for mobilizing bone marrow stem cells in subacute stroke: the stem cell trial of recovery enhancement after stroke 2 randomized controlled trial.
England TJ; Abaei M; Auer DP; Lowe J; Jones DR; Sare G; Walker M; Bath PM
Stroke; 2012 Feb; 43(2):405-11. PubMed ID: 22198983
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow cell mobilization by the systemic use of granulocyte colony-stimulating factor (GCSF) improves wound bed preparation.
Iwamoto S; Lin X; Ramirez R; Carson P; Fiore D; Goodrich J; Yufit T; Falanga V
Int J Low Extrem Wounds; 2013 Dec; 12(4):256-64. PubMed ID: 24275756
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes and graft characteristics in pediatric hematopoietic stem cell transplantation: Effect of granulocyte-colony stimulating factor priming.
Fettah A; Özbek N; Azık F; Tavil B; Özgüner M; Avcı Z; Işık P; Yaralı N; Uçkan D; Tunç B
Transfus Apher Sci; 2015 Jun; 52(3):332-8. PubMed ID: 25779226
[TBL] [Abstract][Full Text] [Related]
5. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
[TBL] [Abstract][Full Text] [Related]
6. [Randomized clinical study for two types of recombinant human granulocyte colony-stimulating factor mobilizing peripheral blood and bone marrow stem cells in patients receiving allogeneic hematopoietic stem cell transplantation].
Zhang XH; Huang XJ; Liu DH; Liu KY; Han W; Chen H; Wang FR; Chen YH; Wang JZ; Zhao T; Wang Y; Xu LP
Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(30):2116-9. PubMed ID: 20058615
[TBL] [Abstract][Full Text] [Related]
7. Mobilization of hematopoietic stem cells by depleting bone marrow macrophages.
Barbier V; Winkler IG; Lévesque JP
Methods Mol Biol; 2012; 904():117-38. PubMed ID: 22890928
[TBL] [Abstract][Full Text] [Related]
8. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
9. Effect of FLT3 ligand and granulocyte colony-stimulating factor on expansion and mobilization of facilitating cells and hematopoietic stem cells in mice: kinetics and repopulating potential.
Neipp M; Zorina T; Domenick MA; Exner BG; Ildstad ST
Blood; 1998 Nov; 92(9):3177-88. PubMed ID: 9787154
[TBL] [Abstract][Full Text] [Related]
10. Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial.
Lonial S; Akhtari M; Kaufman J; Torre C; Lechowicz MJ; Flowers C; Sinha R; Khoury HJ; Langston AA; Waller EK
Biol Blood Marrow Transplant; 2013 Mar; 19(3):460-7. PubMed ID: 23201472
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of mobilization of hematopoietic progenitors with granulocyte colony-stimulating factor.
Thomas J; Liu F; Link DC
Curr Opin Hematol; 2002 May; 9(3):183-9. PubMed ID: 11953662
[TBL] [Abstract][Full Text] [Related]
12. Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow.
Benboubker L; Cartron G; Roingeard F; Delain M; Degenne M; Linassier C; Hérault O; Truglio D; Bout M; Petit A; Brémond JL; Desbois I; Colombat P; Binet C; Domenech J
Exp Hematol; 2003 Jan; 31(1):89-97. PubMed ID: 12543111
[TBL] [Abstract][Full Text] [Related]
13. Stable colony-stimulating factor 1 fusion protein treatment increases hematopoietic stem cell pool and enhances their mobilisation in mice.
Kaur S; Sehgal A; Wu AC; Millard SM; Batoon L; Sandrock CJ; Ferrari-Cestari M; Levesque JP; Hume DA; Raggatt LJ; Pettit AR
J Hematol Oncol; 2021 Jan; 14(1):3. PubMed ID: 33402221
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA126 contributes to granulocyte colony-stimulating factor-induced hematopoietic progenitor cell mobilization by reducing the expression of vascular cell adhesion molecule 1.
Salvucci O; Jiang K; Gasperini P; Maric D; Zhu J; Sakakibara S; Espigol-Frigole G; Wang S; Tosato G
Haematologica; 2012 Jun; 97(6):818-26. PubMed ID: 22271895
[TBL] [Abstract][Full Text] [Related]
15. Progenipoietin-1: a multifunctional agonist of the granulocyte colony-stimulating factor receptor and fetal liver tyrosine kinase-3 is a potent mobilizer of hematopoietic stem cells.
Fleming WH; Mulcahy JM; McKearn JP; Streeter PR
Exp Hematol; 2001 Aug; 29(8):943-51. PubMed ID: 11495700
[TBL] [Abstract][Full Text] [Related]
16. Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice.
Fazzi R; Testi R; Trasciatti S; Galimberti S; Rosini S; Piras F; L'Abbate G; Conte A; Petrini M
Leuk Res; 2002 Jan; 26(1):19-27. PubMed ID: 11734300
[TBL] [Abstract][Full Text] [Related]
17. Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant.
Veeraputhiran M; Jain T; Cronin S; Al-Kadhimi Z; Abidi MH; Ayash L; Mellert K; Lum LG; Ratanatharathorn V; Uberti JP; Deol A
J Clin Apher; 2014 Dec; 29(6):293-8. PubMed ID: 24700728
[TBL] [Abstract][Full Text] [Related]
18. Comparison between granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the mobilization of peripheral blood stem cells.
Gazitt Y
Curr Opin Hematol; 2002 May; 9(3):190-8. PubMed ID: 11953663
[TBL] [Abstract][Full Text] [Related]
19. Hematologic recovery in patients who are treated with autologous stem cells transplantation taken from bone marrow after granulocyte-colony-stimulating factor stimulation.
Gawronski K; Rzepecki P; Oborska S; Wasko-Grabowska A
Transplant Proc; 2011 Oct; 43(8):3114-5. PubMed ID: 21996240
[TBL] [Abstract][Full Text] [Related]
20. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
